Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

ESTUDIOS


01 enero 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: An expert consensus document from the society for cardiovascular angiography and interventions (SCAI)

Issam D. Moussa MD1,*, Lloyd W. Klein MD2, Binita Shah MD3, Roxana Mehran MD4, Michael J. Mack MD5, Emmanouil S. Brilakis MD6, John P. Reilly MD7, Gilbert Zoghbi MD8, Elizabeth Holper MD9, Gregg W. Stone MD10

Numerous definitions have been proposed for the diagnosis of myocardial infarction (MI) after coronary revascularization. The universal definition for MI designates post procedural biomarker thresholds for defining percutaneous coronary intervention (PCI)-related MI (type 4a) and coronary artery bypass grafting (CABG)-related MI (type 5) which are of uncertain prognostic importance. In addition, for both MI types cTn is recommended as the biomarker of choice, the prognostic significance of which is less well validated than CK-MB. Widespread adoption of a MI definition not clearly linked to subsequent adverse events such as mortality or heart failure may have serious consequences for the appropriate assessment of devices and therapies, may affect clinical care pathways, and may result in misinterpretation of physician competence. Rather than employing an MI definition sensitive for small degrees of myonecrosis (the occurrence of which, based on contemporary large-scale studies, are unlikely to have important clinical consequences), it is instead recommended that a threshold level of biomarker elevation which has been strongly linked to subsequent adverse events in clinical studies be used to define a “clinically relevant MI.” The present document introduces a new definition for "clinically relevant MI" after coronary revascularization (PCI or CABG) which is applicable for use in clinical trials, patient care, and quality outcomes assessment. © 2013 Wiley Periodicals, Inc.

01 enero 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. The myocardium supplied by a chronic total occlusion is a persistently ischemic zone

Rajesh Sachdeva MD1,2,*, Mayank Agrawal MD2, Shawn E. Flynn MD2, Gerald S. Werner MD3, Barry F. Uretsky MD2

Well-developed collaterals to a myocardial segment supplied by a chronic total occlusion (CTO) and/or left ventricular dysfunction in the CTO regions in patients with chronic stable angina suggest that severe ischemia is unlikely to be present. We evaluated the presence and severity of ischemia using fractional flow reserve (FFR) of the myocardium supplied by a CTO in patients and compared the results with a non-CTO control group.

01 enero 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: A sub-analysis of the BRAVO study

Brian O´Neill MD1, Vikas Singh MD1, Annapoorna Kini MD2, Roxana Mehran MD2, Evan Jacobs MD1, David Knopf BS1, Carlos E. Alfonso MD1, Claudia A. Martinez MD1, Pedro Martinezclark MD1, William O´Neill MD1, Alan W. Heldman MD1, Jennifer Yu MD2, Usman Baber MD2, Jason C. Kovacic MD2, George Dangas MD2, Samin Sharma MD2, Samantha Sartori PhD2, Mauricio G. Cohen MD1,*

Objective: To determine the impact of suture-mediated vascular closure devices (VCDs) on net adverse clinical events (NACEs) after balloon aortic valvuloplasty (BAV).

01 enero 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. A comparison of the femoral and radial crossover techniques for vascular access management in transcatheter aortic valve implantation: The milan experience

Helen Curran MD, FRCPC, Alaide Chieffo MD, Gill Louise Buchanan MBCHB, Chiara Bernelli MD, Matteo Montorfano MD, Francesco Maisano MD, Azeem Latib MD, Davide Maccagni RT, Mauro Carlino MD, Filippo Figini MD, Micaela Cioni MD, Giovanni La Canna MD, Remo Daniel Covello MD, Annalisa Franco MD, Chiara Gerli MD, Ottavio Alfieri MD, Antonio Colombo MD*

Objective: To compare radial and femoral crossover techniques (CT) for vascular access management in transcatheter aortic valve implantation (TAVI).

01 enero 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. High pacing rates for management of aortic insufficiency after balloon aortic valvuloplasty or transcatheter aortic valve replacement

Omar Ali MD, FACC, Michael H. Salinger MD, FACC, FSCAI, Justin P. Levisay MD, FACC, FSCAI, Ted Feldman MD, FESC, FACC, FSCAI*

Aortic insufficiency (AI) after transcatheter aortic valve replacement (TAVR) is difficult to manage when associated with congestive heart failure. AI after balloon aortic valvuloplasty (BAV) may be catastrophic, especially in patients who are not candidates for TAVR. We describe the use of urgent temporary pacing, followed by permanent pacing, to increase the heart rate to diminish diastolic filling time for the short term management of AI after BAV or TAVR. The strategy is particularly useful in patients who already have permanent pacemakers, which are common in this population. © 2013 Wiley Periodicals, Inc.

01 enero 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Transradial intervention for patients with ST elevation myocardial infarction with or without cardiogenic shock

Toshiharu Fujii MD, Naoki Masuda MD, Takeshi Ijichi MD, Yoshinari Kamiyama MD, Shigemitsu Tanaka MD, Gaku Nakazawa MD, Norihiko Shinozaki MD, PhD, Takashi Matsukage MD, PhD, Nobuhiko Ogata MD, PhD, Yuji Ikari MD, PhD*

Objectives: To compare clinical outcomes between transradial (TRI) and transfemoral intervention (TFI) in primary percutaneous coronary intervention (PCI) in patients with ST elevation myocardial infarction (STEMI) with or without shock.

01 enero 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. A simple preprocedural score for risk of contrast-induced acute kidney injury after percutaneous coronary intervention

Yong-Li Chen MD, Nai-Kuan Fu MD, Jing Xu MD, Shi-Cheng Yang MD, Shanshan Li MD, Yuan-Yuan Liu MD, Hong-Liang Cong MD*

Objective: To develop a simple scoring system based on preprocedural clinical features that is capable of predicting contrast-induced acute kidney injury (CI-AKI) before percutaneous coronary intervention (PCI).

01 enero 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Intracoronary and retrograde coronary venous myocardial delivery of adipose-derived stem cells in swine infarction lead to transient myocardial trapping with predominant pulmonary redistribution

Soon Jun Hong MD, PHD1,2,3,4, Dongming Hou MD, PHD1,2,3, Todd J. Brinton MD5, Brian Johnstone PHD1,2,3, Dongni Feng BS3, Pamela Rogers LATG1,2,3, William F. Fearon MD5, Paul Yock MD5, Keith L. March MD, PHD1,2,3,6,*

Objectives: To examine the comparative fate of adipose-derived stem cells (ASCs) as well as their impact on coronary microcirculation following either retrograde coronary venous (RCV) or arterial delivery. Background: Local delivery of ASCs to the heart has been proposed as a practical approach to limiting the extent of myocardial infarction. Mouse models of mesenchymal stem cell effects on the heart have also demonstrated significant benefits from systemic (intravenous) delivery, prompting a question about the advantage of local delivery. There has been no study addressing the extent of myocardial vs. systemic disposition of ASCs in large animal models following local delivery to the myocardium. Methods: In an initial experiment, dose-dependent effects of ASC delivery on coronary circulation in normal swine were evaluated to establish a tolerable ASC dosing range for intracoronary (IC) delivery. In a set of subsequent experiments, an anterior acute myocardial infarction (AMI) was created by balloon occlusion of the proximal left anterior descending (LAD) artery, followed by either IC or RCV infusion of 107 111Indium-labeled autologous ASCs 6 days following AMI. Indices of microcirculatory resistance (IMR) and coronary flow reserve (CFR) were measured before sacrifices to collect tissues for analysis at 1 or 24 hr after cell delivery. Results: IC delivery of porcine ASCs to normal myocardium was well tolerated up to a cumulative dose of 14 × 106 cells (approximately 0.5 × 106 cells/kg). There was evidence suggesting microcirculatory trapping of ASC: at unit doses of 50 × 106 ASCs, IMR and CFR were found to be persistently altered in the target LAD distribution at 7 days following delivery, whereas at 10 × 106 ASCs, only CFR was altered. In the context of recent MI, a significantly higher percentage of ASCs was retained at 1 hr with IC delivery compared with RCV delivery (57.2 ± 12.7% vs. 17.9 ± 1.6%, P = 0.037) but this initial difference was not apparent at 24 hr (22.6 ± 5.5% vs. 18.7 ± 8.6%; P = 0.722). In both approaches, most ASC redistributed to the pulmonary circulation by 24 hr postdelivery. There were no significant differences in CFR or IMR following ASC delivery to infarcted tissue by either route. Conclusions: Selective intravascular delivery of ASC by coronary arterial and venous routes leads to similarly limited myocardial cell retention with predominant redistribution of cells to the lungs. IC arterial delivery of ASC leads to only transiently greater myocardial retention, which is accompanied by obstruction of normal regions of coronary microcirculation at higher doses. The predominant intrapulmonary localization of cells following local delivery via both methods prompts the notion that systemic delivery of ASC might provide similarly beneficial outcomes while avoiding risks of inadvertent microcirculatory compromise.

01 octubre 2012

AMERICAN HEART JOURNAL. Silent cerebral infarcts after cardiac catheterization: A randomized comparison of radial and femoral approaches

Martial Hamon, MD , Janusz Lipiecki , Didier Carrié , Francesco Burzotta , Nicolas Durel , Guillaume Coutance , Nicolas Boudou , Cesare Colosimo , Carlo Trani , Nicolas Dumonteil , Rémy Morello , Fausto Viader , Béatrice Claise , Michèle Hamon

Background: Single center studies using serial cerebral diffusion-weighted magnetic resonance imaging in patients having cardiac catheterization have suggested that cerebral microembolism might be responsible for silent cerebral infarct (SCI) as high as 15% to 22%. We evaluated in a multicenter trial the incidence of SCIs after cardiac catheterization and whether or not the choice of the arterial access site might impact this phenomenon.

01 noviembre 2013

CIRCULATION. Transcatheter Aortic Valve Replacement for Degenerative Bioprosthetic Surgical Valves. Results From the Global Valve-in-Valve Registry

Danny Dvir, MD; John Webb, MD; Stephen Brecker, MD; Sabine Bleiziffer, MD; David Hildick-Smith, MD; Antonio Colombo, MD; Fleur Descoutures, MD; Christian Hengstenberg, MD; Neil E. Moat, FRCS; Raffi Bekeredjian, MD; Massimo Napodano, MD; Luca Testa, MD, PhD; Thierry Lefevre, MD; Victor Guetta, MD; Henrik Nissen, MD, PhD; José-María Hernández, MD; David Roy, MD; Rui C. Teles, MD; Amit Segev, MD; Nicolas Dumonteil, MD; Claudia Fiorina, MD; Michael Gotzmann, MD; Didier Tchetche, MD; Mohamed Abdel-Wahab, MD; Federico De Marco, MD; Andreas Baumbach, MD; Jean-Claude Laborde, MD; Ran Kornowski, MD

Background—Transcatheter aortic valve-in-valve implantation is an emerging therapeutic alternative for patients with a failed surgical bioprosthesis and may obviate the need for reoperation. We evaluated the clinical results of this technique using a large, worldwide registry.

01 octubre 2012

AMERICAN HEART JOURNAL. Ankle-brachial index and cardiovascular outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial

J. Dawn Abbott, MDemail address , Manuel S. Lombardero, MS , Gregory W. Barsness, MD , Ivan Pena-Sing, MD , L. Virginia Buitrón, MD , Premranjan Singh, MD , Gail Woodhead, RN , Jean-Claude Tardif, MD , Sheryl F. Kelsey, PhD

Background: Peripheral arterial disease increases cardiovascular risk in many patient populations. The risks associated with an abnormal ankle-brachial index (ABI) in patients with type 2 diabetes and stable coronary artery disease have not been well described with respect to thresholds and types of cardiovascular events.

01 noviembre 2012

AMERICAN JOURNAL OF CARDIOLOGY. Diabetes and Cardiovascular Disease: Changing the Focus from Glycemic Control to Improving Long-Term Survival

Cecilia C. Low Wang, MD , Jane E.B. Reusch, MD

Diabetes mellitus (DM) is the fifth-leading cause of death worldwide and contributes to leading causes of death, cancer and cardiovascular disease, including CAD, stroke, peripheral vascular disease, and other vascular disease. While glycemic management remains a cornerstone of DM care, the co-management of hypertension, atherosclerosis, cardiovascular risk reduction, and prevention of long-term consequences associated with DM are now well recognized as essential to improve long-term survival. Clinical trial evidence substantiates the importance of glycemic control, low-density cholesterol–lowering therapy, blood pressure lowering, control of albuminuria, and comprehensive approaches targeting multiple risk factors to reduce cardiovascular risk. This article presents a review of the role of DM in the pathogenesis of atherosclerosis and cardiac dysfunction, recent evidence on the degree of glycemic control and mortality, and available evidence for a multifaceted approach to improve long-term outcomes for patients.

01 noviembre 2012

JACC: CARDIOVASCULAR INTERVENTIONS. Time-Dependent Detrimental Effects of Distal Embolization on Myocardium and Microvasculature During Primary Percutaneous Coronary Intervention

Massimo Napodano, MD?; Diletta Peluso, MD?; Martina Perazzolo Marra, MD?; Anna Chiara Frigo, MSc†; Giuseppe Tarantini, MD, PhD?; Paolo Buja, MD, PhD?; Valeria Gasparetto, MD?; Chiara Fraccaro, MD?; Giambattista Isabella, MD?; Renato Razzolini, MD?; Sabino Iliceto, MD?

Objectives: The authors sought to investigate the impact of distal embolization (DE) on myocardial damage and microvascular reperfusion, according to time-to-treatment, using contrast-enhanced cardiac magnetic resonance (CE-CMR).

01 octubre 2013

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Acute outcome of stent therapy for coarctation of the aorta: Results of the coarctation of the aorta stent trial

Richard E. Ringel MD1, Julie Vincent MD2, Kathy J. Jenkins MD, MPH3, Kimberlee Gauvreau ScD3, Heidi Moses MEd, CCRA3, Kimberly Lofgren BA3, Kudret Usmani BA, BSc3

Objectives: The coarctation of the aorta stent trial (COAST) is a pivotal trial of the NuMED Cheatham Platinum Stent® for treatment of coarctation of the aorta (CoA).

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.